重组人尿激酶原治疗发病4.5小时内急性缺血性卒中的有效性与安全性:3期随机临床试验
这项中国35个医疗中心开展的3期随机、阿替普酶对照、开放标签试验,于2018年5月至2020年5月纳入674例18至80岁、发病4.5小时内的急性缺血性卒中患者,1:1随机接受静脉重组人尿激酶原或阿替普酶。改良意向治疗人群663例中,90天改良Rankin量表评分0至1分的比例在重组人尿激酶原组为65.2%,阿替普酶组为64.3%(风险差0.89,95.4%CI -6.52至8.29),符合预先设定的非劣效界值(组间差异小于10%)。症状性颅内出血两组分别为1.5%和1.8%(P > .99),90天内全身出血重组人尿激酶原组25.8%低于阿替普酶组42.2%(P < .001),溶栓相关死亡两组均为1.5%(P > .99)。
要点
- 主要终点90天改良Rankin量表评分0至1分:重组人尿激酶原组65.2% vs 阿替普酶组64.3%,风险差0.89(95.4%CI -6.52至8.29),满足非劣效界值(差异小于10%)。
- 症状性颅内出血:重组人尿激酶原组1.5% vs 阿替普酶组1.8%,P > .99。
- 90天内全身出血:重组人尿激酶原组25.8% vs 阿替普酶组42.2%,P < .001,阿替普酶组更常见。
- 溶栓相关死亡:重组人尿激酶原组1.5% vs 阿替普酶组1.5%,P > .99。
适用人群与场景
- 年龄18至80岁、诊断为急性缺血性卒中并在发病4.5小时内接受治疗的患者。
诊断标准与关键阈值
- 非劣效界值:组间差异小于10%。
- 主要终点:90天改良Rankin量表评分0至1分。
处置流程与药物剂量
- 符合条件的患者按1:1随机接受静脉重组人尿激酶原或阿替普酶。
研究设计与关键结果
- 研究类型:随机、阿替普酶对照、开放标签、3期临床试验;2018年5月至2020年5月在中国35个医疗中心开展;筛查684例,纳入674例。
- 改良意向治疗人群663例:平均(SD)年龄61.00(10.20)岁,女性161例(24.3%);重组人尿激酶原组330例,阿替普酶组333例。
- 基线美国国立卫生研究院卒中量表评分中位数(IQR)为6.00(5.00-9.00)。
- 死亡23例,619例(93.4%)完成3个月随访。
- 主要终点(90天改良Rankin量表评分0至1分):重组人尿激酶原组215例(65.2%) vs 阿替普酶组214例(64.3%),风险差0.89(95.4%CI -6.52至8.29)。
- 症状性颅内出血:重组人尿激酶原组5例(1.5%) vs 阿替普酶组6例(1.8%)(P > .99)。
- 90天内全身出血:阿替普酶组141例(42.2%)多于重组人尿激酶原组85例(25.8%)(P < .001)。
- 90天内溶栓相关死亡:重组人尿激酶原组5例(1.5%) vs 阿替普酶组5例(1.5%)(P > .99)。
证据类型、等级与局限
- 证据类型:随机、阿替普酶对照、开放标签、3期临床试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,发病4.5小时内急性缺血性卒中静脉重组人尿激酶原不劣于阿替普酶,症状性颅内出血发生率相似,全身出血更少。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Recombinant human prourokinase (rhPro-UK) is a thrombolytic agent that has shown promising findings in a phase 2 clinical trial in patients with acute ischemic stroke (AIS).
OBJECTIVE: To evaluate the efficacy and safety of rhPro-UK thrombolysis within 4.5 hours of symptom onset in patients with AIS.
DESIGN, SETTING, AND PARTICIPANTS: This randomized, alteplase-controlled, open-label, phase 3 clinical trial was conducted from May 2018 to May 2020 at 35 medical centers in China. A total of 684 patients were screened and 674 patients were enrolled. Included patients were aged 18 to 80 years with a diagnosis of AIS and received treatment within 4.5 hours of stroke onset. Data were analyzed from June to October 2020.
INTERVENTIONS: Eligible patients were randomly assigned (1:1) to receive intravenous rhPro-UK or alteplase.
MAIN OUTCOMES AND MEASURES: The primary objective was to assess whether rhPro-UK was noninferior to alteplase. The noninferiority margin was a between-group difference of less than 10%. The primary outcome was a modified Rankin Scale score of 0 to 1 at 90 days.
RESULTS: Among 663 patients in the modified intention-to-treat population (mean [SD] age, 61.00 [10.20] years; 161 females [24.3%]), there were 330 patients in the rhPro-UK group and 333 patients in the alteplase group. The median (IQR) baseline National Institutes of Health Stroke Scale score was 6.00 (5.00-9.00). There were 23 deaths, and 619 patients (93.4%) completed the 3-month follow-up. The primary outcome occurred in 215 patients (65.2%) in the rhPro-UK group and 214 patients (64.3%) in the alteplase group (risk difference, 0.89; 95.4% CI, -6.52 to 8.29). Symptomatic intracerebral hemorrhage occurred in 5 patients (1.5%) in the rhPro-UK group and 6 patients (1.8%) in the alteplase group (P > .99). Systemic bleeding within 90 days occurred more frequently in the alteplase group (141 patients [42.2%]) than the rhPro-UK group (85 patients [25.8%]) (P < .001). By 90 days, 5 thrombolysis-related deaths each had occurred in the rhPro-UK group (1.5%) and alteplase group (1.5%) (P > .99).
CONCLUSIONS AND RELEVANCE: This study found that intravenous rhPro-UK within 4.5 hours of AIS onset was noninferior to alteplase. The rhPro-UK group showed a similar rate of symptomatic ICH but fewer cases of systemic bleeding than the alteplase group.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03541668.
参考来源
- Song H, Wang Y, Ma Q, et al. Efficacy and Safety of Recombinant Human Prourokinase in the Treatment of Acute Ischemic Stroke Within 4.5 Hours of Stroke Onset: A Phase 3 Randomized Clinical Trial. JAMA Netw Open. 2023. PMID: 37490291. doi:10.1001/jamanetworkopen.2023.25415
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。